The estimated Net Worth of Pharmaceutical Inc. Ultragenyx is at least $154 Million dollars as of 10 August 2021. Pharmaceutical Ultragenyx owns over 800,000 units of Arcturus Therapeutics Inc stock worth over $29,372,000 and over the last 4 years Pharmaceutical sold ARCT stock worth over $124,280,000.
Pharmaceutical has made over 3 trades of the Arcturus Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Pharmaceutical sold 800,000 units of ARCT stock worth $43,632,000 on 10 August 2021.
The largest trade Pharmaceutical's ever made was selling 800,000 units of Arcturus Therapeutics Inc stock on 10 August 2021 worth over $43,632,000. On average, Pharmaceutical trades about 733,333 units every 149 days since 2020. As of 10 August 2021 Pharmaceutical still owns at least 1,400,000 units of Arcturus Therapeutics Inc stock.
You can see the complete history of Pharmaceutical Ultragenyx stock trades at the bottom of the page.
Pharmaceutical's mailing address filed with the SEC is 60, Leveroni Court, Ignacio, Novato, Marin County, California, 94949, United States of America.
Over the last 12 years, insiders at Arcturus Therapeutics Inc have traded over $137,035,874 worth of Arcturus Therapeutics Inc stock and bought 56,234 units worth $767,374 . The most active insiders traders include William M Kahane, Nicholas S Schorsch, and Peter C Farrell. On average, Arcturus Therapeutics Inc executives and independent directors trade stock every 33 days with the average trade being worth of $1,034,818. The most recent stock trade was executed by Jing L. Marantz on 14 June 2024, trading 3,131 units of ARCT stock currently worth $65,688.
founded in 2013 and based in san diego, calif., arcturus therapeutics is poised to become an industry leader in the application of rnai technologies for the treatment of disease and improved quality of life. the company’s aim is to develop breakthrough technology and novel therapeutics for rare diseases for which there is no adequate treatment. backed by a management team with extensive experience in the discovery and development of therapeutic modalities, arcturus is on the forefront of research and development of nanoparticle sirna drug delivery systems.
Arcturus Therapeutics Inc executives and other stock owners filed with the SEC include: